Neurodegenerative disorders and nanoformulated drug development.
about
Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicinesMethods for isolation and identification of nanoparticle-containing subcellular compartments.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.In silico theoretical molecular modeling for Alzheimer's disease: the nicotine-curcumin paradigm in neuroprotection and neurotherapy.Registered bioimaging of nanomaterials for diagnostic and therapeutic monitoring.Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.Neurological disorders and therapeutics targeted to surmount the blood-brain barrierNeuropharmacologic Approaches to Restore the Brain's Microenvironment.Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriageAstroglial transcriptome dysregulation in early disease of an ALS mutant SOD1 mouse model.Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model.Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications.Multifunctionalized CMCht/PAMAM Dendrimer Nanoparticles Modulate the Cellular Uptake by Astrocytes and Oligodendrocytes in Primary Cultures of Glial Cells
P2860
Q26850868-F7556FB1-9E5D-4B7E-9A75-863B86DED550Q33561837-CEFC7016-DA9D-4AE1-A448-A87E16A988F5Q33625213-619344BA-6EBB-4B47-8EEC-D028AD149CA7Q33826249-E879456F-075B-4364-B868-819C02985D81Q34639915-5EBBAE7B-7861-435C-B7A1-E5F2ACBB5308Q35606068-FAABFF77-E920-4B6B-A176-F8822CA5F302Q36107193-C9AC5DE4-A95B-45DA-9808-EB0C094E99E2Q36119574-7F2F6523-7E75-4E0D-841C-F0729052BABDQ38879533-39897B40-06CC-42F1-92A5-BD56B9FA5869Q41972161-38FAB533-EB93-41A5-85E1-F3D0C54E9BECQ42116659-DB1D31EB-7231-4E49-AF7C-1DA5656C4F06Q48381628-3CE66916-7E68-470C-91D3-48B17FAE0D5FQ48794611-7BF1A5ED-0103-4724-8444-F0266460B79DQ50023771-E7968C2A-1420-4271-8DA2-BD6183A70763Q57171366-29CDF4D8-FAD6-42CC-9170-0F7790E28FD6
P2860
Neurodegenerative disorders and nanoformulated drug development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neurodegenerative disorders and nanoformulated drug development.
@en
Neurodegenerative disorders and nanoformulated drug development.
@nl
type
label
Neurodegenerative disorders and nanoformulated drug development.
@en
Neurodegenerative disorders and nanoformulated drug development.
@nl
prefLabel
Neurodegenerative disorders and nanoformulated drug development.
@en
Neurodegenerative disorders and nanoformulated drug development.
@nl
P2093
P2860
P356
P1433
P1476
Neurodegenerative disorders and nanoformulated drug development.
@en
P2093
Ari Nowacek
Howard E Gendelman
Lisa M Kosloski
P2860
P304
P356
10.2217/NNM.09.37
P577
2009-07-01T00:00:00Z